Roles of heterogenous hepatic macrophages in the progression of liver diseases

키워드

참고문헌 (99)

1. Sanyal A, "Zakim and Boyer’s hepatology: a textbook of liver disease" (2017), Elsevier
2. Koyama Y, "Liver inflammation and fibrosis", J Clin Invest, 127, pp.55~64 (2017)
3. Lopez BG, "Characterization of Kupffer cells in livers of developing mice", Comp Hepatol, 10, pp.2~ (2011)
4. Chen Y, "Innate lymphocytes : pathogenesis and therapeutic targets of liver diseases and cancer", Cell Mol Immunol, 18, pp.57~72 (2021)
5. Tacke F, "Targeting hepatic macrophages to treat liver diseases", J Hepatol, 66, pp.1300~1312 (2017)
6. Tacke F, "Macrophage heterogeneity in liver injury and fibrosis", J Hepatol, 60, pp.1090~1096 (2014)
7. Scott CL, "Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells", Nat Commun, 7, pp.10321~ (2016)
8. Stutchfield BM, "CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure", Gastroenterology, 149, pp.1896~1909 (2015)
9. Nascimento M, "Ly6Chi monocyte recruitment is responsible for Th2 associated host-protective macrophage accumulation in liver inflammation due to schistosomiasis", PLoS Pathog, 10, pp.e1004282~ (2014)
10. Zigmond E, "Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury", J Immunol, 193, pp.344~353 (2014)
11. Krenkel O, "Liver macrophages in tissue homeostasis and disease", Nat Rev Immunol, 17, pp.306~321 (2017)
12. Fogg DK, "A clonogenic bone marrow progenitor specific for macrophages and dendritic cells", Science, 311, pp.83~87 (2006)
13. Kupffer C, "Ueber Sternzellen der Leber", Archiv für mikroskopische Anatomie, 12, pp.353~358 (1876)
14. Browicz, "Ueber intravasculäre Zellen in den Blutcapillaren der Leberacini", Archiv für mikroskopische Anatomie, 55, pp.420~426 (1899)
15. van Furth R, "The mononuclear phagocyte system : a new classification of macrophages, monocytes, and their precursor cells", Bull World Health Organ, 46, pp.845~852 (1972)
16. Yona S, "Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis", Immunity, 38, pp.79~91 (2013)
17. Hoeffel G, "C-Myb(+)erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages", Immunity, 42, pp.665~678 (2015)
18. Mass E, "Specification of tissue-resident macrophages during organogenesis", Science, 353, pp.aaf4238~ (2016)
19. Mass E, "Delineating the origins, developmental programs and homeostatic functions of tissue-resident macrophages", Int Immunol, 30, pp.493~501 (2018)
20. Gomez Perdiguero E, "Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors", Nature, 518, pp.547~551 (2015)
21. Bertrand JY, "Three pathways to mature macrophages in the early mouse yolk sac", Blood, 106, pp.3004~3011 (2005)
22. Beattie L, "Bone marrowderived and resident liver macrophages display unique transcriptomic signatures but similar biological functions", J Hepatol, 65, pp.758~768 (2016)
23. Heymann F, "Immunology in the liver--from homeostasis to disease", Nat Rev Gastroenterol Hepatol, 13, pp.88~110 (2016)
24. Heymann F, "Liver inflammation abrogates immunological tolerance induced by Kupffer cells", Hepatology, 62, pp.279~291 (2015)
25. Strnad P, "Liver-guardian, modifier and target of sepsis", Nat Rev Gastroenterol Hepatol, 14, pp.55~66 (2017)
26. Helmy KY, "CRIg : a macrophage complement receptor required for phagocytosis of circulating pathogens", Cell, 124, pp.915~927 (2006)
27. Zeng Z, "CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne Gram-positive bacteria", Cell Host Microbe, 20, pp.99~106 (2016)
28. Jenne CN, "Immune surveillance by the liver", Nat Immunol, 14, pp.996~1006 (2013)
29. Zheng M, "Liver-mediated adaptive immune tolerance", Front Immunol, 10, pp.2525~ (2019)
30. Baeck C, "Pharmacological inhibition of the chemokine CCL2(MCP-1)diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury", Gut, 61, pp.416~426 (2012)
31. Karlmark KR, "Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis", Hepatology, 50, pp.261~274 (2009)
32. Miura K, "Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2", Am J Physiol Gastrointest Liver Physiol, 302, pp.G1310~ (2012)
33. Varol C, "Monocytes give rise to mucosal, but not splenic, conventional dendritic cells", J Exp Med, 204, pp.171~180 (2007)
34. Ramachandran P, "Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis", Proc Natl Acad Sci U S A, 109, pp.3186~3195 (2012)
35. Mossanen JC, "Chemokine(C-C motif)receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury", Hepatology, 64, pp.1667~1682 (2016)
36. David BA, "Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice", Gastroenterology, 151, pp.1176~1191 (2016)
37. Auffray C, "Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior", Science, 317, pp.666~670 (2007)
38. Serbina NV, "Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2", Nat Immunol, 7, pp.311~317 (2006)
39. Swirski FK, "Identification of splenic reservoir monocytes and their deployment to inflammatory sites", Science, 325, pp.612~616 (2009)
40. Bonnardel J, "Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche", Immunity, 51, pp.638~654 (2019)
41. Sakai M, "Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity", Immunity, 51, pp.655~670 (2019)
42. Blériot C, "Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection", Immunity, 42, pp.145~158 (2015)
43. Braga TT, "Macrophages during the fibrotic process : M2 as friend and foe", Front Immunol, 6, pp.602~ (2015)
44. Gao B, "Inflammation in alcoholic and nonalcoholic fatty liver disease : friend or foe?", Gastroenterology, 150, pp.1704~1709 (2016)
45. Grunhut J, "Macrophages in nonalcoholic steatohepatitis : friend or foe?", Eur Med J Hepatol, 6, pp.100~109 (2018)
46. Duffield JS, "Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair", J Clin Invest, 115, pp.56~65 (2005)
47. Ritz T, "Dynamic plasticity of macrophage functions in diseased liver", Cell Immunol, 330, pp.175~182 (2018)
48. Devisscher L, "Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool", Cell Immunol, 322, pp.74~83 (2017)
49. Lefere S, "Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtypespecific markers", J Hepatol, 71, pp.631~633 (2019)
50. Tran S, "Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis", Immunity, 53, pp.627~640 (2020)
51. Ramachandran P, "Resolving the fibrotic niche of human liver cirrhosis at single-cell level", Nature, 575, pp.512~518 (2019)
52. Xiong X, "Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis", Mol Cell, 75, pp.644~660 (2019)
53. Jaitin DA, "Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner", Cell, 178, pp.686~698 (2019)
54. Wang Y, "TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model", Cell, 160, pp.1061~1071 (2015)
55. Hou J, "TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis", J Clin Invest, 131, pp.e135197~ (2021)
56. Perugorria MJ, "Non-parenchymal TREM-2 protects the liver from immunemediated hepatocellular damage", Gut, 68, pp.533~546 (2019)
57. Guillot A, "Liver macrophages : old dogmas and new insights", Hepatol Commun, 3, pp.730~743 (2019)
58. Wen Y, "Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities", Cell Mol Immunol, 18, pp.45~56 (2021)
59. Franchi L, "The inflammasome : a caspase-1-activation platform that reguates immune responses and disease pathogenesis", Nat Immunol, 10, pp.241~247 (2009)
60. Szabo G, "Inflammasome activation and function in liver disease", Nat Rev Gastroenterol Hepatol, 12, pp.387~400 (2015)
61. Mridha AR, "NLRP3inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice", J Hepatol, 66, pp.1037~1046 (2017)
62. Zhang C, "Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity", Cell Mol Immunol, 15, pp.973~982 (2018)
63. Melgar-Lesmes P, "Monocyte-endothelial cell interactions in the regulation of vascular sprouting and liver regeneration in mouse", J Hepatol, 63, pp.917~925 (2015)
64. Guo Q, "Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH", J Hepatol, 71, pp.1193~1205 (2019)
65. Cai J, "The role of innate immune cells in nonalcoholic steatohepatitis", Hepatology, 70, pp.1026~1037 (2019)
66. Soehnlein O, "Phagocyte partnership during the onset and resolution of inflammation", Nat Rev Immunol, 10, pp.427~439 (2010)
67. Sutti S, "CX3CR1 mediates the development of monocyte-derived dendritic cells during hepatic inflammation", Cells, 8, pp.1099~ (2019)
68. Wehr A, "Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis", J Immunol, 190, pp.5226~5236 (2013)
69. Jiang Y, "Kupffer cell receptor CLEC4F is important for the destruction of desialylated platelets in mice", Cell Death Differ, 28, pp.3009~3021 (2021)
70. Malehmir M, "Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer", Nat Med, 25, pp.641~655 (2019)
71. Seidman JS, "Nichespecific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis", Immunity, 52, pp.1057~1074 (2020)
72. Daemen S, "Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH", Cell Rep, 34, pp.108626~ (2021)
73. Chakarov S, "Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches", Science, 363, pp.eaau0964~ (2019)
74. Chen G, "Single-cell RNA-Seq technologies and related computational data analysis", Front Genet, 10, pp.317~ (2019)
75. Lambrecht J, "Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis", Expert Opin Pharmacother, 21, pp.1637~1650 (2020)
76. Ju C, "Hepatic macrophages in homeostasis and liver diseases : from pathogenesis to novel thera-peutic strategies", Cell Mol Immunol, 13, pp.316~327 (2016)
77. van der Heide D, "Therapeutic targeting of hepatic macrophages for the treatment of liver diseases", Front Immunol, 10, pp.2852~ (2019)
78. Krenkel O, "Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis", Hepatology, 67, pp.1270~1283 (2018)
79. Kruger AJ, "Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis", Hepatol Commun, 2, pp.529~545 (2018)
80. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
81. Ratziu V, "Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis : final analysis of the phase 2b CENTAUR study", Hepatology, 72, pp.892~905 (2020)
82. Anstee QM, "Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis : AURORA Phase 3 study design", Contemp Clin Trials, 89, pp.105922~ (2020)
83. Pérez-Martínez L, "Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease(NAFLD)", J Antimicrob Chemother, 69, pp.1903~1910 (2014)
84. Mulder P, "The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and nonalcoholic steatohepatitis", PLoS One, 12, pp.e0169740~ (2017)
85. Albillos A, "The gut-liver axis in liver disease : pathophysiological basis for therapy", J Hepatol, 72, pp.558~577 (2020)
86. Dapito DH, "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", Cancer Cell, 21, pp.504~516 (2012)
87. Schneider KM, "CX3CR1is a gatekeeper for intestinal barrier integrity in mice : Limiting steatohepatitis by maintaining intestinal homeostasis", Hepatology, 62, pp.1405~1416 (2015)
88. Seki E, "TLR4enhances TGF-beta signaling and hepatic fibrosis", Nat Med, 13, pp.1324~1332 (2007)
89. Carpino G, "Increased liver localization of lipopolysaccharides in human and experimental NAFLD", Hepatology, 72, pp.470~485 (2020)
90. Bennett RG, "Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis", World J Gastroenterol, 23, pp.3999~4006 (2017)
91. Weiskirchen R, "Liver fibrosis : from pathogenesis to novel therapies", Dig Dis, 34, pp.410~422 (2016)
92. Loomba R, "The ASK1inhibitor selonsertib in patients with nonalcoholic steatohepatitis : a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
93. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
94. Han YH, "RORα induces KLF4-mediated M2 polarization in the liver macrophages that protect against nonalcoholic steatohepatitis", Cell Rep, 20, pp.124~135 (2017)
95. Han YH, "A maresin 1", RORα, J Clin Invest, pp.2019, 129[DOI]
96. Henderson NC, "Galectin-3 regulates myofibroblast activation and hepatic fibrosis", Proc Natl Acad Sci U S A, 103, pp.5060~5065 (2006)
97. Iacobini C, "Galectin-3ablation protects mice from diet-induced NASH : a major scavenging role for galectin-3 in liver", J Hepatol, 54, pp.975~983 (2011)
98. Chalasani N, "Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345 (2020)
99. Lefere S, "Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages", J Hepatol, 73, pp.757~770 (2020)

관련 논문AI추천